Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dapagliflozin for prevention of contrast-induced acute kidney injury after coronary angiography
IRCT20251230068494N1Phase 3Completed
- Sponsor
- Shiraz University of Medical Sciences
- Start
- Feb 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dapagliflozin in acute kidney failure (AKF) (6 arms), sponsored by Shiraz University of Medical Sciences. Primary endpoints: Change in serum creatinine at 48-72 hours from baseline, Occurrence of contrast-induced acute kidney injury and 3 more. Started Feb 2026; status: completed.
02
Drugs
dapagliflozin
03
Conditions
acute kidney failure (AKF)
Beyond the preview
Go deeper on IRCT20251230068494N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20251230068494N1.